611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Pandemic Is Driving U.S. Surge in Cardiac Arrests Tied to OverdoseAmericans With Asthma Get First Updated Guidelines in Over a DecadePandemic Is Devastating Low-Income Black HouseholdsObesity Ups Women's Odds for Early Hip FractureFootball-Loving States Drop The Ball on Concussion: StudyCOVID Can Harm the Infant HeartCDC Director Warns of Dire Winter Ahead for COVID Hospitalizations, DeathsRelief for America's Unemployed Could Be Crucial for HealthMany Hospitalized COVID Patients Will Need Longer-Term Care at HomeCDC Shrinks COVID Quarantine Time, Advises Against Holiday TravelShould Cancer Survivors Be Prioritized for COVID Vaccine?Take Care of Your Mental Health During PandemicGay, Lesbian Adults Often Miss Out on Cholesterol MedsBritain Approves Emergency Use of Pfizer's COVID VaccineHealth Care Workers, Nursing Home Residents to Get First Vaccines: PanelNeed an IV or Stitches? Virtual Reality or Hypnosis Might Ease PainCOVID-19 Can Damage Lungs So Badly That 'Only Hope' is TransplantPandemic Could Be Golden Time for Narcissists: Study'Smell Training' Might Speed the Sense's Return After COVIDEye Injury Reported From Germ-Killing UV LampsCOVID Hospitalizations in U.S. Hit Record High'Repeat After Me' for Better Diabetes CareVentilators May Leave COVID Survivors With Windpipe InjuriesLockdown Loneliness Could Worsen Parkinson's SymptomsDiabetes, High Blood Pressure Raise Odds of COVID Harming BrainCOVID in Kids: The Most Telling SymptomsFauci Warns of Another Surge of COVID Cases After Thanksgiving TravelWood-Fired Cooking a Cause of Lung Illness in Developing WorldDelirium May Be Only Sign of Severe COVID in Elderly: StudySimple Move May Boost Spinal Fusion OutcomesCould the TB Vaccine Help Prevent COVID-19?When COVID Strikes Cancer Patients, Men Fare WorseMost Americans Over 50 Would Get COVID Vaccine: PollAnother Study Casts Doubt on 'Convalescent Plasma' as COVID-19 TreatmentCOVID Vaccine Rollout Could Begin Mid-December, Fauci SaysFauci: 'People Should Feel Confident' New COVID Vaccines Safe, EffectiveCould the Pill Reduce Asthma Attacks?Coronavirus Most Contagious Soon After InfectionPeople Should Know That COVID Vaccine Might Spur Transient Sickness: CDC ExpertsAnother Study Finds COVID Usually Mild in KidsBlacks, Hispanics Account for More Than Half of COVID Deaths: StudyCollege Kid Coming Home for Thanksgiving? Here's How to Keep Your Family SafeParents' Age Key to Whether Kids Get Vaccinated Against COVID, Study FindsVegan Diets Tied to Higher Bone Fracture RiskThird COVID Vaccine Shows Effectiveness; FDA Approves New TreatmentWhich Kids With COVID Will Get Very Sick?Add Kids to COVID Vaccine Trials, Pediatricians' Group SaysLosing Your Hair Because of Pandemic Stress?How Hospitals Can Cut Patients' FallsMany Young Americans Lonely, Depressed During Pandemic: Survey
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Chinese COVID Vaccine Appears Safe, Effective

HealthDay News
by Robert Preidt
Updated: Nov 18th 2020

new article illustration

WEDNESDAY, Nov. 18, 2020 (HealthDay News) -- A Chinese COVID-19 vaccine seems to be safe and effective, early trial results suggest, but one expert says the findings should be regarded with caution.

The CoronaVac vaccine is based on inactivated SARS-CoV-2 virus. It was tested in a phase 1/2 clinical trial that included more than 700 healthy volunteers, ages 18-59, who were recruited in China between April 16 and May 5.

The vaccine appeared to be safe and well-tolerated at all tested doses, researchers reported. The most common reported side effect was pain at the injection site.

Even at the lowest dose tested (3 micrograms), participants had strong antibody responses within two weeks of the second and final dose. Shots were given 14 days apart.

Though levels of antibodies triggered by the vaccine were lower than those in recovered coronavirus patients, researchers said they still believe the vaccine could provide protection from the virus.

They noted that the trial's primary objective was to evaluate the vaccine's immune response and safety. It wasn't designed to assess how effective the vaccine is in preventing infection with SARS-CoV-2.

The findings were published Nov. 17 in The Lancet Infectious Diseases journal.

After taking into account side effects and other factors, the researchers determined that a dose of 3 mcg prompted the highest antibody response. This will be investigated further in phase 3 trials now underway.

"Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunization by giving two doses of the vaccine at a 14-day interval. We believe that this makes the vaccine suitable for emergency use during the pandemic," said co-lead author Fengcai Zhu of the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, China.

"In the longer term, when the risk of COVID-19 is lower, our findings suggest that giving two doses with a one-month interval, rather than a two-week interval, might be more appropriate for inducing stronger and potentially longer-lasting immune responses. However, further studies are needed to check how long the antibody response remains after either vaccination schedule," Zhu said in a journal news release.

CoronaVac is one of 48 COVID-19 vaccine candidates now in clinical trials.

Naor Bar-Zeev, an associate professor in the Division of Global Disease Epidemiology and Control at Johns Hopkins University in Baltimore, wrote an editorial that accompanied the findings.

"Like all phase 2 trials, the results must be interpreted with caution until phase 3 results are published," he wrote. "But even then, after phase 3 trial completion and after licensure, we should prudently remain cautious."

More information

For more on COVID-19 vaccines, go to the U.S. Centers for Disease Control and Prevention.

SOURCE: The Lancet Infectious Diseases, news release, Nov. 17, 2020